lax and cobicistat; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and cobicistat is a CYP3A4 and P-gp inhibitor. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If cobicistat is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate: Avoid the concomitant use of venetoclax and cobicistat; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and cobicistat is a CYP3A4 and P-gp inhibitor. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If cobicistat is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Colchicine: Avoid the concomitant use of venetoclax and colchicine as colchicine levels may be increased. If concomitant use of these drugs is required, administer colchicine at least 6 hours before venetoclax. Monitor patients for signs and symptoms of colchicine toxicity. Venetoclax is an inhibitor of P-glycoprotein (P-gp) and colchicine is a P-gp substrate with a narrow therapeutic index; these agents may interact in the gastrointestinal tract.
Conivaptan: Avoid the concomitant use of venetoclax and conivaptan; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and conivaptan is a strong CYP3A4 and P-gp inhibitor. The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax. If concomitant use of these drugs is required when the patient is on a steady venetoclax dose (after the titration phase), reduce the venetoclax dosage by at least 75% (maximum dose of 100 mg/day). If conivaptan is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study, the venetoclax Cmax and AUC values were increased by 2.3-fold and 6.4-fold, respectively, when a strong CYP3A4 inhibitor was co-administered in NHL patients.
Crizotinib: Avoid the concomitant use of venetoclax and crizotinib; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and crizotinib is a CYP3A4 (moderate) and P-gp inhibitor. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If crizotinib is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis s |
